CMC Pharma offers small molecule drug development services designed to accelerate your program while reducing risk. Our integrated approach spans formulation and process development, analytical chemistry services, stability and compatibility testing, and method transfer execution, ensuring that every data point generated is scientifically robust and submission-ready.
Unlike traditional CDMOs, contract testing labs, or regulatory consulting firms, CMC Pharma is a single, full-service development partner. Our approach to small molecule drug development combines consulting services with lab execution and regulatory strategy. This one-partner model eliminates hand-offs, reduces misalignment, and avoids costly delays associated with multiple vendors or external consultants.
Our services are designed to help you move faster and more efficiently from early drug discovery through clinical development and commercialization, with built-in regulatory guidance.
Early drug development is where programs are won or lost. The decisions made in pre-formulation and early formulation, such as which salt form to advance, which dosage form to pursue, how to address solubility or stability challenges, have downstream consequences that ripple through clinical development, regulatory submissions, and ultimately, commercialization. Getting expert drug development support services in place at this stage is a strategic necessity.
CMC Pharma’s early small molecule drug development services are designed to provide that expertise from day one. Our scientists work alongside your team during the pre-formulation phase to evaluate the physicochemical properties of your API, assess solubility and stability, and identify the most viable path forward for your target product profile. We conduct early feasibility studies, excipient compatibility assessments, and candidate selection evaluations. This is the foundational work that determines whether your program advances efficiently or encounters costly, avoidable setbacks later.
From pre-formulation through IND-enabling studies, our integrated model ensures that formulation development, analytical method development, and early stability data are all generated in alignment with FDA and ICH expectations. Every study is designed with regulatory strategy in mind, so the data package you bring to your IND submission is complete, defensible, and built on a scientific foundation that will hold up across the drug development lifecycle. This is where our drug development consulting services add the most value. We don’t just execute studies, but we advise on which studies to run, in what sequence, and why.
Whether you are advancing a first-in-class small molecule, addressing a challenging API with poor solubility, or seeking to accelerate a program that has stalled in early development, CMC Pharma provides the scientific depth and strategic clarity to move forward with confidence. Our early-stage capabilities are fully integrated with our downstream manufacturing enablement and regulatory support services, meaning that when you are ready to scale, you already have an established partner to help you get there.
CMC Pharma’s small molecule drug development services span the full drug development cycle from feasibility and early-stage formulation to clinical readiness and commercial launch. By integrating lab, manufacturing, and regulatory expertise, we:
Partner with CMC Pharma for drug development services that are fast, flexible, and fully integrated. We combine scientific expertise, regulatory foresight, and operational excellence to advance your small molecule and complex drug programs efficiently and successfully.
Whether you need to develop robust analytical methods or require routine testing, Contact CMC Pharma to learn how we can help you advance your pharmaceutical development program.
Send us a message or give us a call at 440-485-1734
